How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
1, 2026, while advancing late-stage trials for its lead breast cancer therapy palazestrant and progressing an oral KAT6 inhibitor program. Despite this leadership change, investor attention has intensified as analysts highlight palazestrant's potential in the large endocrine therapy market and Olema's plans for possible U.S. filing and ex-U.S. partnerships if upcoming Phase 3 results are positive. With Olema's management transition coinciding with advancing Phase 3 palazestrant trials, we'll assess how this shapes the company's investment narrative. The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it . Find the list for free. What Is Olema Pharmaceuticals' Investment Narrative? To own Olema Pharmaceuticals, you have to believe its lead asset palazestrant can convert strong clinical execution in ER+ breast cancer into a real commercial foothold, while the rest of the pipeline and cash runway sup
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMABusiness Wire
- Olema Pharmaceuticals (OLMA) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 3/11/26 - Form 144
- 3/10/26 - Form 144
- 3/9/26 - Form 144
- OLMA's page on the SEC website